About Us
Abingworth has been investing in life science companies since the early days of the biotechnology industry.
As the industry’s footprint and experience grew, so did ours: from one office in London with a handful of investments to a transatlantic operation that has invested in over 180 companies. The experience and expertise we have accumulated as a result are, we believe, key assets for our portfolio companies.
Abingworth’s Transatlantic Reach
Even in the age of instant electronic communication, there is no substitute for face-to-face discussions and informal get-togethers. That’s why we have offices in key biotech hubs in both the US and Europe, so that we can interact more productively with the entrepreneurs we support. These offices also enable us to tap more effectively into the deep talent pools and scientific networks in and around those hubs.
Meet the team- 192
Life Science Companies
- 36
Product Approvals
Since 2012 - 75
IPOs
- 52
M&A
- 30
Abingworth Team
- 16
CCD Deals
Learn More
15 Life Science Funds
Abingworth has raised 15 funds dedicated to investing in life sciences and healthcare.
Our most recent venture fund, Abingworth Bioventures 8, raised $466 million while Abingworth’s Clinical Co-Development Fund 2 and Clinical Co-Development Co-Investment Fund raised $466 million and $356 million respectively. All are actively investing.
The funds invest in private and public companies across three broad strategic areas: seed and early stage, development stage (including VIPEs and public markets) and clinical co-development.